Patients choose their own treatment in landmark myelofibrosis study

NCT ID NCT04217356

First seen Jan 06, 2026 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This study compares a stem cell transplant to the best available non-transplant treatments for people with high-risk myelofibrosis, a serious bone marrow cancer. About 90 participants will choose which treatment they prefer, and researchers will track survival and quality of life over time. The goal is to see which approach offers better outcomes for this challenging condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cross Cancer Institute

    Edmonton, Alberta, T6G2G3, Canada

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, B3H2Y9, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G2M9, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, V6E1M7, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N4N2, Canada

Conditions

Explore the condition pages connected to this study.